Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Portfolio Pulse from
Sonnet BioTherapeutics has announced the issuance of a U.S. patent for a variant IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1411 and SON-1400. These proteins show wild-type binding to the IL-18 receptor while avoiding binding to the inhibitory IL-18 binding protein.
November 06, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonnet BioTherapeutics has been granted a U.S. patent for its novel drug candidates SON-1411 and SON-1400, which could enhance their market potential.
The issuance of a U.S. patent for SON-1411 and SON-1400 is a significant milestone for Sonnet BioTherapeutics, as it strengthens their intellectual property portfolio and enhances the commercial potential of these drug candidates. This development is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100